⭕️Watch the full episode👉 https://ept.ms/2YnViDX
⭕️ Watch in-depth videos based on Truth & Tradition at Epoch TV👉 https://ept.ms/3j1W0gX
Despite high vaccine coverage and effectiveness, the incidence of symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been increasing in Israel. Whether the increasing incidence of infection is due to waning immunity after the receipt of two doses of the BNT162b2 vaccine is unclear.
As the rollout of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1,2 is expanding worldwide, data on the durability of protection are limited. A randomized, controlled trial and real-world studies have shown vaccine efficacy of 94 to 95% with the BNT162b2 vaccine (Pfizer–BioNTech) and vaccine effectiveness in preventing symptomatic coronavirus disease 2019 (Covid-19) 7 days or more after receipt of the second dose of vaccine.1,3–5 Real-world effectiveness and immunogenicity data describing the antibody kinetics over time after vaccination are beginning to appear, but a complete picture of the duration of immunity is not yet available. We recently reported that breakthrough infection in BNT162b2-vaccinated persons was correlated with neutralizing antibody titers.6 However, a threshold titer that can predict breakthrough infection has not been defined.
The BNT162b2 vaccine elicits high IgG and neutralizing antibody responses 7 to 14 days after receipt of the second dose. Lower antibody levels have been shown to develop in older persons, men, and persons with an immunosuppressed condition, which suggests that antibody titers in these populations may decrease earlier than in other populations.7,8 A decrease in anti-spike (S) antibody levels by a factor of two was observed from the peak (at 21 to 40 days) to 84 days after receipt of the second dose of the BNT162b2 vaccine among 197 vaccinated persons.9 Here, we report the results of a large-scale, real-world, longitudinal study involving health care workers that was conducted to assess the kinetics of immune response among persons with different demographic characteristics and coexisting conditions throughout the 6-month period after receipt of the second dose of the BNT162b2 vaccine.
Analytics has played a significant role in the fight against COVID-19. Would we be as far along in the battle without it?
The COVID-19 pandemic has changed many things in business, producing a new normal that all of us now operate in—and analytics is no exception.
“As companies adapt to the new normal created by COVID, one of the primary questions we’re asked in analytics is how to retrain artificial intelligence (AI) models with a more diverse data set,” said David Tareen, director of AI and analytics at SAS.
Dr. Hans Recknagel, who led the field and genome research during his Ph.D. and postdoctoral research, said: This was fascinating research, not least because in this species of lizard egg-laying populations still occur and interbreed with live-bearing ones.
Scientists studying the evolution of birth in lizards, from egg-laying to live births, have pinpointed the evolutionary genes from which the species is evolving to ‘build’ a new mode of reproduction.
The study—led by the University of Glasgow and published in Nature Ecology and Evolution —found that a significantly similar amount of the same genes involved in the pregnancy of lizards were shared with other mammals and live-bearing vertebrates.
A FIVE-DAY COURSE of molnupiravir, the new medicine being hailed as a “huge advance” in the treatment of Covid-19, costs $17.74 to produce, according to a report (pdf) issued last week by drug pricing experts at the Harvard School of Public Health and King’s College Hospital in London. Merck is charging the U.S. government $712 for the same amount of medicine, or 40 times the price. (taxpayer funded mind you)
The Covid-19 treatment molnupiravir was developed using funding from the National Institutes of Health and the Department of Defense.
Scientists also analysed microbial genetic material from the stool of men with prostate cancer and identified a specific bacterium – Ruminococcus – that may play a major role in the development of resistance. In contrast, the bacterium Prevotella stercorea was associated with favourable clinical outcomes.
Image: Section of a mouse gut. Credit: Kevin Mackenzie, University of Aberdeen.
Common gut bacteria can fuel the growth of prostate cancers and allow them to evade the effects of treatment, a new study finds.
Continue reading “‘Gut bugs’ can drive prostate cancer growth and treatment resistance” »
Specialized cells that conduct electricity to keep the heart beating have a previously unrecognized ability to regenerate in the days after birth, a new study in mice by UT Southwestern researchers suggests. The finding, published online in the Journal of Clinical Investigation, could eventually lead to treatments for heart rhythm disorders that avoid the need for invasive pacemakers or drugs by instead encouraging the heart to heal itself.
“Patients with arrhythmias don’t have a lot of great options,” said study leader Nikhil V. Munshi, M.D., Ph.D., a cardiologist and Associate Professor of Internal Medicine, Molecular Biology, and in the Eugene McDermott Center for Human Growth and Development. “Our findings suggest that someday we may be able to elicit regeneration from the heart itself to treat these conditions.”
Dr. Munshi studies the cardiac conduction system, an interconnected system of specialized heart muscle cells that generate electrical impulses and transmit these impulses to make the heart beat. Although studies have shown that nonconducting heart muscle cells have some regenerative capacity for a limited time after birth—with many discoveries in this field led by UTSW scientists—conducting cells called nodal cells were largely thought to lose this ability during the fetal period.
Exclusive: Report from planning exercise in 2016 alerted government of need to stockpile PPE and set up contact tracing system.
It probably didn’t feel like much, but that simple kind of motion required the concerted effort of millions of different neurons in several regions of your brain, followed by signals sent at 200 mph from your brain to your spinal cord and then to the muscles that contracted to move your arm.
At the cellular level, that quick motion is a highly complicated process and, like most things that involve the human brain, scientists don’t fully understand how it all comes together.
